DOI: 10.5176/2315-4330_WNC16.95

Authors: Nnenna Weathers, Marcel Fomotar, Michele M. Maison-Fomotar, Beth R. Hoffman, Angela L. Hudson


Aims: To explore barriers and facilitators to using and adhering to Truvada, among HIV-negative, post-incarcerated, African American MSM (MSM). Background: African American MSM represent only 2{6e6090cdd558c53a8bc18225ef4499fead9160abd3419ad4f137e902b483c465} of the U.S. population, yet account for 73{6e6090cdd558c53a8bc18225ef4499fead9160abd3419ad4f137e902b483c465} of new HIV infections among African American men. Truvada was FDA approved in 2012 for chemoprophylaxis in HIV-negative persons at high HIV risk. According to CDC guidelines, Truvada is most efficacious when used daily in addition to consistent condom use from the beginning to end of sex, and with 2-3 month medical checks and counseling. Methods: We used convenience and snowball sampling. Participants were recruited in collaboration with the Center for Health Justice and Men’s Central Jail in Los Angeles. Data were gathered using semi-structured questions in one and one half hour, audio-recorded, focus group sessions. Analysis: Transcripts were analyzed using AtlasTi qualitative software. Findings: 1. HIV-related stigma continues in African American communities 2. HIV-negative post-incarcerated African American MSM may not consistently use or adhere to Truvada 3. Use of Truvada may mean that the user is HIV positive or gay, and 4. African American MSM may not use condoms with Truvada. 5. MSM who are incarcerated should be given Truvada.

Keywords: Truvada, African American, HIV

Price: $4.99

Loading Updating cart...